乙型肝炎和丙型肝炎与2型糖尿病的关系

覃超梅; 刘永明; 苏何玲

doi:10.3969/j.issn.1001-5256.2021.04.042

乙型肝炎和丙型肝炎与2型糖尿病的关系

DOI: 10.3969/j.issn.1001-5256.2021.04.042

桂林医学院生物化学与分子生物学教研室，广西桂林 541004

基金项目:

国家自然科学基金项目 (81560341);

国家自然科学基金项目 (81460320);

广西自然科学基金资助项目 (2018GXNSFAA138153)

利益冲突声明：所有作者均不存在利益冲突。

作者贡献声明：覃超梅负责文献查阅、资料数据分析以及文章撰写；刘永明负责文字修改，并参与拟定写作思路；苏何玲负责拟定写作思路和指导撰写文章并最后定稿。

详细信息

作者简介:
覃超梅(1996—)，女，主要从事HBV感染相关分子疾病研究

通信作者:
苏何玲，helingsu@glmc.edu.cn

中图分类号: R512.6;R587.1
计量
- 文章访问数: 516
- HTML全文浏览量: 155
- PDF下载量: 55
- 被引次数: 0
出版历程
- 收稿日期: 2020-11-10
- 录用日期: 2020-12-16
- 出版日期: 2021-04-20

Association of hepatitis B and hepatitis C with type 2 diabetes mellitus

Department of Biochemistry and Molecular Biology, Guilin Medical University, Guilin, Guangxi 541004, China

摘要

摘要:
乙型肝炎和丙型肝炎以及2型糖尿病(T2DM)均为全球性的严重公共卫生问题。分析了乙型和丙型肝炎与T2DM的关系。分析表明，一方面，乙型肝炎和丙型肝炎均促进T2DM发病，其发病机制涉及病毒感染抑制胰岛素信号转导和胰岛素靶细胞葡萄糖摄取以及糖原合成。另一方面，T2DM患者容易罹患乙型肝炎和丙型肝炎，这可能与糖尿病导致多种器官功能的破坏有关。
- 乙型肝炎 /
- 丙型肝炎 /
- 糖尿病, 2型
Abstract:
Hepatitis B, hepatitis C, and type 2 diabetes mellitus (T2DM) are serious public health issues worldwide. This article analyzes the association of hepatitis B and hepatitis C with T2DM. The analysis shows that on the one hand, both hepatitis B and hepatitis C promote the pathogenesis of T2DM, which involves viral infection inhibiting insulin signal transduction as well as glucose uptake and glycogen synthesis in insulin target cells; on the other hand, patients with T2DM are prone to hepatitis B and hepatitis C, which may be associated with multiple organ dysfunction caused by diabetes.
- Hepatitis B /
- Hepatitis C /
- Diabetes Mellitus, Type 2

HTML全文

图 1 HBV及HCV蛋白作用于胰岛素信号通路

下载: 全尺寸图片幻灯片

表 1 HBV作用于胰岛素信号途径相关因子

HBV蛋白	胰岛素信号通路相关因子	机制	参考文献
pre-S2	INSR	下调INSR基因启动子的活性，降低INSR的表达	[12-13]
HBx	IRS-1	HBx与前列腺六次跨膜蛋白2蛋白相互作用并降低其稳定性，阻止IRS-1蛋白降解	[14, 16]
HBx	Akt	激活肝细胞中的PI3K/Akt	[15, 17]
HBx	GSK-3β	激活Akt并导致下游GSK-3β磷酸化，降低肝糖的合成	[18-19]
HBx	PDK1	上调PI3K的下游效应分子PDK1的表达	[20]

下载: 导出CSV

表 2 HCV作用于胰岛素信号途径相关因子

HCV蛋白	胰岛素信号途径相关因子	机制	参考文献
HCV core	TNFα	上调TNFα，导致IRS-1/IRS-2的丝氨酸氨基酸磷酸化	[32]
HCV core	SOCS3	上调SOCS3，导致IRS-1/IRS-2降解	[33]
HCV core	GLUT2	下调GLUT2的细胞表达，从而抑制葡萄糖摄取	[44]

下载: 导出CSV

参考文献(50)

[1]	World Health Organization. Global hepatitis report, 2017[EB/OL]. [2020-11-10]. https://www.who.int/hepatitis/publications/global-hepatitis-report2017/en/externalicon.
[2]	International Diabetes Federation. Diabetes Atlas. 9th Edition. 2019[EB/OL]. [2020-11-10]. https://diabetesatlas.org/data/en/world/International.
[3]	FABIANI S, FALLAHI P, FERRARI SM, et al. Hepatitis C virus infection and development of type 2 diabetes mellitus: Systematic review and meta-analysis of the literature[J]. Rev Endocr Metab Disord, 2018, 19(4): 405-420. DOI: 10.1007/s11154-017-9440-1.
[4]	HONG YS, CHANG Y, RYU S, et al. Hepatitis B and C virus infection and diabetes mellitus: A cohort study[J]. Sci Rep, 2017, 7(1): 4606. DOI: 10.1038/s41598-017-04206-6.
[5]	HAN BF, YUAN QL, LIU J, et al. The risk of hepatitis B virus infection in people with diabetes mellitus: A meta-analysis[J]. Chin J Prevent Med, 2018, 52(7): 748-752. DOI: 10.3760/cma.j.issn.0253-9624.2018.07.013. 韩冰峰, 袁千里, 刘姜, 等. 糖尿病患者感染HBV风险的Meta分析[J]. 中华预防医学杂志, 2018, 52(7): 748-752. DOI: 10.3760/cma.j.issn.0253-9624.2018.07.013.
[6]	SINGH KK, PANDA SK, SHALIMAR, et al. Patients with diabetes mellitus are prone to develop severe hepatitis and liver failure due to hepatitis virus infection[J]. J Clin Exp Hepatol, 2013, 3(4): 275-280. DOI: 10.1016/j.jceh.2013.11.003.
[7]	ZHANG J, SHEN Y, CAI H, et al. Hepatitis B virus infection status and risk of type 2 diabetes mellitus: A meta-analysis[J]. Hepatol Res, 2015, 45(11): 1100-1109. DOI: 10.1111/hepr.12481.
[8]	CAI C, ZENG J, WU H, et al. Association between hepatitis B virus infection and diabetes mellitus: A meta-analysis[J]. Exp Ther Med, 2015, 10(2): 693-698. DOI: 10.3892/etm.2015.2537.
[9]	WU D. Correlation of viral load of hepatitis B with the gestation period and the development of diabetes mellitus[J]. Saudi J Biol Sci, 2019, 26(8): 2022-2025. DOI: 10.1016/j.sjbs.2019.08.009.
[10]	GILES ML, DAVEY MA, WALLACE EM. Chronic hepatitis B infection and the risk of gestational diabetes: A cross-sectional study[J]. BJOG, 2020, 127(9): 1147-1152. DOI: 10.1111/1471-0528.16217.
[11]	YE J, HU X, WU T, et al. Insulin resistance exhibits varied metabolic abnormalities in nonalcoholic fatty liver disease, chronic hepatitis B and the combination of the two: A cross-sectional study[J]. Diabetol Metab Syndr, 2019, 11: 45. DOI: 10.1186/s13098-019-0440-z.
[12]	JI D, HAN P, ZHANG J, et al. Down-regulating effect of hepatitis B virus pre-S2 protein upon insulin receptor gene promoter[J]. Chin J Prevent Med, 2009, 89(43): 3069-3073. DOI: 10.3760/cma.j.issn.0376-2491.2009.43.013. 纪冬, 韩萍, 张健, 等. 乙型肝炎病毒前S2蛋白下调胰岛素受体启动子的研究[J]. 中华医学杂志, 2009, 89(43): 3069-3073. DOI: 10.3760/cma.j.issn.0376-2491.2009.43.013.
[13]	BARTHEL SR, MEDVEDEV R, HEINRICH T, et al. Hepatitis B virus inhibits insulin receptor signaling and impairs liver regeneration via intracellular retention of the insulin receptor[J]. Cell Mol Life Sci, 2016, 73(21): 4121-4140. DOI: 10.1007/s00018-016-2259-1.
[14]	KIM HY, CHO HK, YOO SK, et al. Hepatic STAMP2 decreases hepatitis B virus X protein-associated metabolic deregulation[J]. Exp Mol Med, 2012, 44(10): 622-632. DOI: 10.3858/emm.2012.44.10.071.
[15]	RAWAT S, BOUCHARD MJ. The hepatitis B virus (HBV) HBx protein activates AKT to simultaneously regulate HBV replication and hepatocyte survival[J]. J Virol, 2015, 89(2): 999-1012. DOI: 10.1128/JVI.02440-14.
[16]	CHUNG W, KIM M, de la MONTE S, et al. Activation of signal transduction pathways during hepatic oncogenesis[J]. Cancer Lett, 2016, 370(1): 1-9. DOI: 10.1016/j.canlet.2015.09.016.
[17]	ZHU M, GUO J, LI W, et al. HBx induced AFP receptor expressed to activate PI3K/AKT signal to promote expression of Src in liver cells and hepatoma cells[J]. BMC Cancer, 2015, 15: 362. DOI: 10.1186/s12885-015-1384-9.
[18]	KHATTAR E, MUKHERJI A, KUMAR V. Akt augments the oncogenic potential of the HBx protein of hepatitis B virus by phosphorylation[J]. FEBS J, 2012, 279(7): 1220-1230. DOI: 10.1111/j.1742-4658.2012.08514.x.
[19]	PIRACHA ZZ, KWON H, SAEED U, et al. Sirtuin 2 isoform 1 enhances hepatitis B virus RNA transcription and DNA synthesis through the AKT/GSK-3β/β-catenin signaling pathway[J]. J Virol, 2018, 92(21): e00955-18. DOI: 10.1128/JVI.00955-18.
[20]	LI C, LIN C, CONG X, et al. PDK1-WNK1 signaling is affected by HBx and involved in the viability and metastasis of hepatic cells[J]. Oncol Lett, 2018, 15(4): 5940-5946. DOI: 10.3892/ol.2018.8001.
[21]	ZHOU Y, CUI Y, DENG H, et al. Association between hepatitis B virus infection and metabolic syndrome: A retrospective cohort study in Shanghai, China[J]. BMC Public Health, 2014, 14: 516. DOI: 10.1186/1471-2458-14-516.
[22]	LI Y, ZHAO Y, WU J. Serum HBV surface antigen positivity is associated with low prevalence of metabolic syndrome: A meta-analysis[J]. PLoS One, 2017, 12(5): e0177713. DOI: 10.1371/journal.pone.0177713.
[23]	KUO YH, KEE KM, WANG JH, et al. Association between chronic viral hepatitis and metabolic syndrome in southern Taiwan: A large population-based study[J]. Aliment Pharmacol Ther, 2018, 48(9): 993-1002. DOI: 10.1111/apt.14960.
[24]	WANG CC, CHENG PN, KAO JH. Systematic review: Chronic viral hepatitis and metabolic derangement[J]. Aliment Pharmacol Ther, 2020, 51(2): 216-230. DOI: 10.1111/apt.15575.
[25]	LIU J, SHI JP. Diagnosis and treatment of hepatitis B virus infection complicated by metabolic syndrome[J]. J Clin Hepatol, 2016, 32(11): 2039-2042. DOI: 10.3969/j.issn.1001-5256.2016.11.004. 刘静, 施军平. HBV感染合并代谢综合征的诊治[J]. 临床肝胆病杂志, 2016, 32(11): 2039-2042. DOI: 10.3969/j.issn.1001-5256.2016.11.004.
[26]	ZHANG X, ZHU X, JI Y, et al. Increased risk of hepatitis B virus infection amongst individuals with diabetes mellitus[J]. Biosci Rep, 2019, 39(3): BSR20181715. DOI: 10.1042/BSR20181715.
[27]	YOUNOSSI Z, STEPANOVA M, SAAB S, et al. The association of hepatitis C virus infection and post-liver transplant diabetes: Data from 17: BSR20181715000 HCV-infected transplant recipients[J]. Aliment Pharmacol Ther, 2015, 41(2): 209-217. DOI: 10.1111/apt.13027.
[28]	BANKS DE, BOGLER Y, BHUKET T, et al. Significant disparities in risks of diabetes mellitus and metabolic syndrome among chronic hepatitis C virus patients in the U. S[J]. Diabetes Metab Syndr, 2017, 11 Suppl 1: s153-s158. DOI: 10.1016/j.dsx.2016.12.025.
[29]	CHEN Y, JI H, SHAO J, et al. Different hepatitis C virus infection statuses show a significant risk of developing type 2 diabetes mellitus: A network meta-analysis[J]. Dig Dis Sci, 2020, 65(7): 1940-1950. DOI: 10.1007/s10620-019-05918-7.
[30]	GUO X, JIN M, YANG M, et al. Type 2 diabetes mellitus and the risk of hepatitis C virus infection: A systematic review[J]. Sci Rep, 2013, 3: 2981. DOI: 10.1038/srep02981.
[31]	GEBREKRISTOS G, TEWELDEMEDHIN M, HAGOS L, et al. Hepatitis C virus infections and associated risk factors in patients with diabetes mellitus; case control study in North West Tigray, Ethiopia[J]. BMC Res Notes, 2018, 11(1): 873. DOI: 10.1186/s13104-018-3983-4.
[32]	BANERJEE S, SAITO K, AIT-GOUGHOULTE M, et al. Hepatitis C virus core protein upregulates serine phosphorylation of insulin receptor substrate-1 and impairs the downstream akt/protein kinase B signaling pathway for insulin resistance[J]. J Virol, 2008, 82(6): 2606-2612. DOI: 10.1128/JVI.01672-07.
[33]	KAWAGUCHI T, YOSHIDA T, HARADA M, et al. Hepatitis C virus down-regulates insulin receptor substrates 1 and 2 through up-regulation of suppressor of cytokine signaling 3[J]. Am J Pathol, 2004, 165(5): 1499-1508. DOI: 10.1016/S0002-9440(10)63408-6.
[34]	PARVAIZ F, MANZOOR S, IQBAL J, et al. Hepatitis C virus NS5A promotes insulin resistance through IRS-1 serine phosphorylation and increased gluconeogenesis[J]. World J Gastroenterol, 2015, 21(43): 12361-12369. DOI: 10.3748/wjg.v21.i43.12361.
[35]	HETTA HF, ELKADY A, MORSY KH, et al. Serum level of IL17a among cirrhotic hepatitis C virus infected patients with incidence of diabetes mellitus[J]. Egypt J Immunol, 2017, 24(1): 79-88. http://europepmc.org/abstract/MED/29120580
[36]	LEMOINE M, CHEVALIEZ S, BASTARD JP, et al. Association between IL28B polymorphism, TNFα and biomarkers of insulin resistance in chronic hepatitis C-related insulin resistance[J]. J Viral Hepat, 2015, 22(11): 890-896. DOI: 10.1111/jvh.12408.
[37]	SHINTANI Y, FUJIE H, MIYOSHI H, et al. Hepatitis C virus infection and diabetes: Direct involvement of the virus in the development of insulin resistance[J]. Gastroenterology, 2004, 126(3): 840-848. DOI: 10.1053/j.gastro.2003.11.056.
[38]	KASAI D, ADACHI T, DENG L, et al. HCV replication suppresses cellular glucose uptake through down-regulation of cell surface expression of glucose transporters[J]. J Hepatol, 2009, 50(5): 883-894. DOI: 10.1016/j.jhep.2008.12.029.
[39]	DAS P, BISWAS S, MUKHERJEE S, et al. Association of oxidative stress and obesity with insulin resistance in type 2 diabetes mellitus[J]. Mymensingh Med J, 2016, 25(1): 148-152. http://www.ncbi.nlm.nih.gov/pubmed/26931265
[40]	DENG L, SHOJI I, OGAWA W, et al. Hepatitis C virus infection promotes hepatic gluconeogenesis through an NS5A-mediated, FoxO1-dependent pathway[J]. J Virol, 2011, 85(17): 8556-8568. DOI: 10.1128/JVI.00146-11.
[41]	SMIRNOVA OA, IVANOVA ON, BARTOSCH B, et al. Hepatitis C virus NS5A protein triggers oxidative stress by inducing NADPH oxidases 1 and 4 and cytochrome P450 2E1[J]. Oxid Med Cell Longev, 2016, 2016: 8341937. DOI: 10.1155/2016/8341937.
[42]	YANG Y, WANG Y, KONG Y, et al. Carnosine prevents type 2 diabetes-induced osteoarthritis through the ROS/NF-κB pathway[J]. Front Pharmacol, 2018, 9: 598. DOI: 10.3389/fphar.2018.00598.
[43]	ANTICOLI S, AMATORE D, MATARRESE P, et al. Erratum to "Counteraction of HCV-induced oxidative stress concurs to establish chronic infection in liver cell cultures"[J]. Oxid Med Cell Longev, 2019, 2019: 3712969. DOI: 10.1155/2019/3712969.
[44]	SHOJI I, DENG L, MATSUI C, et al. Hepatitis C virus-induced glucose metabolic disorder[J]. Uirusu, 2015, 65(2): 263-268. DOI: 10.2222/jsv.65.263.
[45]	CHOI HY, KIM Y, CHO H, et al. Risk of diabetes in viral hepatitis B or C patients compared to that in noninfected individuals in Korea, 2002-2013: A population-based cohort study[J]. J Viral Hepat, 2018, 25(3): 272-280. DOI: 10.1111/jvh.12815.
[46]	CHEN YY, FANG WH, WANG CC, et al. Increased body fat percentage in patients with hepatitis B and C virus infection[J]. PLoS One, 2018, 13(7): e0200164. DOI: 10.1371/journal.pone.0200164.
[47]	LIN PY, CHEN SC, LO TC, et al. Dual infection with hepatitis B virus and hepatitis C virus correlated with type 2 diabetes mellitus[J]. Exp Clin Endocrinol Diabetes, 2020, 128(1): 38-42. DOI: 10.1055/a-0794-6135
[48]	JIN Y, GAO H, CHEN H, et al. Identification and impact of hepatitis B virus DNA and antigens in pancreatic cancer tissues and adjacent non-cancerous tissues[J]. Cancer Lett, 2013, 335(2): 447-454. DOI: 10.1016/j.canlet.2013.03.001.
[49]	SHIKE H, KADRY Z, IMAMURA-KAWASAWA Y, et al. Hepatitis C virus (HCV) RNA level in plasma and kidney tissue in HCV antibody-positive donors: Quantitative comparison[J]. Clin Transplant, 2018, 32(9): e13358. DOI: 10.1111/ctr.13358.
[50]	GUO CH, SUN TT, WENG XD, et al. The investigation of glucose metabolism and insulin secretion in subjects of chronic hepatitis B with cirrhosis[J]. Int J Clin Exp Pathol, 2015, 8(10): 13381-13386. http://europepmc.org/abstract/MED/26722544